866211-50-9

Basic information

• Product Name: 2H-Indol-2-one, 4-fluoro-1,3-dihydro-3,3-dimethyl-
• Synonyms: 2H-Indol-2-one,4-fluoro-1,3-dihydro-3,3-dimethyl;4-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one;5-fluoro-3,3-dimethyl-1,3-dihydroindol-2-one;4-FLUORO-3,3-DIMETHYLINDOLIN-2-ONE
• CAS NO: 866211-50-9
• Molecular Formula: C10H10FNO
• Molecular Weight: 179.19100
• Mol File: 866211-50-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2H-Indol-2-one, 4-fluoro-1,3-dihydro-3,3-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-Indol-2-one, 4-fluoro-1,3-dihydro-3,3-dimethyl-(866211-50-9)
• EPA Substance Registry System: 2H-Indol-2-one, 4-fluoro-1,3-dihydro-3,3-dimethyl-(866211-50-9)

Safety Data

• Hazardous Substances Data: 866211-50-9(Hazardous Substances Data)

Upstream product

• 138343-94-9 4-fluoro-1,3-dihydro-2H-indol-2-one 
• 74-88-4 methyl iodide 
• 913720-03-3 2-(2,3-difluorophenyl)isobutyramide 
• 913720-04-4 2-(2,6-difluorophenyl)isobutyramide 

Downstream Products

• 1357192-71-2 1-cyclobutyl-4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-1(4H)-yl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 
• 1357192-67-6 4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-1(4H)-yl]-3,3-dimethyl-1-(1-methylethyl)-1,3-dihydro-2H-indol-2-one 
• 1357192-26-7 1-(cyclopropylmethyl)-4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-1(4H)-yl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 
• 1357192-09-6 4-fluoro-5-[5-methoxy-4-oxo-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-1(4H)-yl]-1,3,3-trimethyl-1,3-dihydro-2H-indol-2-one 

Relevant articles and documents

Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor

Highly potent and brain-penetrant phosphodiesterase 10A (PDE10A) inhibitors based on the 2-oxindole scaffold were designed and synthesized. (2-Oxo-1,3-oxazolidin-3-yl)phenyl derivative 1 showed the high P-glycoprotein (P-gp) efflux (efflux ratio (ER) = 6.

Progesterone receptor antagonists, contraceptive regimens, and kits

A method of contraception is provided which involves delivery of 21 to 27 consecutive days of one or more PR antagonists in the absence of a progestin, estrogen, or other steroidal compound, followed by 1 to 7 days without any active agent. Also described is a pharmaceutically useful kit to facilitate delivery of this regimen.